https://rijournals.com/public-health-and-pharmacy/

RESEARCH INVENTION JOURNAL OF PUBLIC HEALTH AND PHARMACY 4(1): 12-16, 2025

RIJPP Publications

ISSN ONLINE: 1115-8689

ISSN PRINT 1597-8559

https://doi.org/10.59298/RIJPP/2025/411216

Global Collaborations in Vaccine Development and Distribution

Asiimawe Masika Agnovia

Department of Clinical Medicine and Dentistry Kampala International University Uganda
Email: agnovia.asiimawe@studwc.kiu.ac.ug

ABSTRACT

In an increasingly interconnected world, infectious diseases pose a global threat, necessitating coordinated efforts in vaccine development and distribution. The COVID-19 pandemic highlighted the importance of international collaboration to accelerate vaccine research, manufacturing, and equitable access. This paper examines the historical evolution of vaccine development, the roles of key stakeholders including governments, pharmaceutical companies, and international organizations and the challenges faced in ensuring fair vaccine distribution. Furthermore, it investigates technological advancements such as mRNA vaccines, AI-driven data analytics, and digital health solutions that have enhanced the global response to pandemics. Despite significant progress, issues related to intellectual property rights, geopolitical disparities, and logistical barriers remain unresolved. Strengthening international partnerships, fostering knowledge-sharing, and investing in innovative technologies are essential for building a resilient global vaccine ecosystem. Addressing these challenges will be crucial in preparing for future pandemics and ensuring equitable access to life-saving immunizations.

Keywords: Global health, vaccine development, pandemic response, vaccine equity, international collaboration, COVID-19, technological innovations.

INTRODUCTION

Pathogens know no borders, and infectious diseases spread faster than before in an interconnected world. To bring a pandemic under control, a large share of the world needs to be immune to the virus. This, however, not only requires considerable amounts of vaccines in each country but also a high vaccination coverage across the globe. Leaders of the G20 stated that the COVID-19 crisis will not be over until all countries can bring the disease under control. As such, large-scale, global vaccination is a political priority. To this end, the World Health Organization urged countries to share vaccine doses and keep the COVAX Facility on track to deliver 2 billion doses within 2021; 2.3 billion of the COVID-19 vaccines administered worldwide were distributed in 10 countries; and equitable access to vaccines is still out of reach [1, 2, 3]. The practice of immunization is a global public good, saving millions of lives every year. In 2019, it was estimated that vaccines prevented between 2 and 3 million deaths globally. But the benefits of vaccine coverage go beyond saving lives, as high immunization rates can eventually lead to the eradication of certain infectious diseases, such as being the case for smallpox in the 80s of the previous century, and portending soon for polio. However, achieving equity in vaccine allocation across regions has proven to be challenging. In that context, the term 'public good' will have to be tested against an economist's definition, the conclusion being that vaccines are depletable and are thus not a public good due to their initial scarcity. An alternative additionality criterion will thus be used, namely the reduction in social costs resulting from individuals being immunized. This criterion will be used with caution since the benefits related to reduced social distancing measures may be possibly ambiguous for some vaccines [4, 5, 6].

Historical Overview of Vaccine Development

Vaccination has brought forth the most affordable and efficient healthcare milestone ever achieved by human beings. Several cornerstones have shaped the history of vaccines. Vaccines may contain live-attenuated viruses or bacteria, inactivated (killed) organisms or viruses, inactivated toxins (toxoids), or merely segments of the pathogen that could elicit an immune response in the human host. Multiple types of vaccines are currently available, and several new ones are continually being added to the pavilion. Since the invention in the mid-1800s, vaccination devices have not exhibited considerable development, thus relying on the same principle of hypodermic needles to deliver liquid vaccines despite technological advancements. However, the available vaccines have been overly maximized. The history of vaccines could also be related to earlier forms of disease control, such as variolation and other ancient practices. Importantly, the word vaccine is derived from the word vaccinia - the scientific name of the cowpox virus. This practice was later replaced by a safer procedure, and thereby vaccine, using a cowpox virus. With this inception, Edward Jenner laid down the foundation of vaccination as a process and the birth of immunology as a science, concomitantly providing one of the first definitive explanations of immune memory. The eradication of smallpox in 1980 is likely the pinnacle of vaccine-related scientific achievements. In the 19th and 20th centuries, the scope of vaccines has witnessed a growing expansion, covering an increasing number of infectious diseases. Importantly, vaccines have begun to shift from controlling the disease to an active immunization approach to prevention, owed in large part to microbiological discoveries [7, 8, 9].

Key Players in Global Vaccine Development

Governments, pharmaceutical companies, non-governmental organizations (NGOs), and international organizations have distinct roles in the complex vaccine ecosystem. It is argued that successful vaccine development requires knowing the roles of these important stakeholders, arranging complementary and mutually reinforcing partnerships, fully understanding how inputs to the vaccine ecosystem are influenced by the different stakeholders, and what factors promote effective collaboration among them. Governments are found to be the most significant direct contributors to the vaccine ecosystem, actively funding vaccine research and the delivery of products into the early stages of the vaccine pipeline. Pharmaceuticals, NGOs, and International Organizations are more likely to assume pivotal roles in later phases, in which funding shifts toward clinical testing, regulatory review, and procurement or delivery assistance. Relationships are both complementary and highly interdependent. Pharmaceuticals act as a catalyst, accelerating funding into later stages and encouraging a greater involvement of NGOs and international organizations. In parallel, public actors work to ensure the development of promising vaccine candidates, maintaining a relatively high funding level into the commercialization stage. Success is at least partially predicated on the active engagement of pharmaceuticals, including how novel strategies can be developed to encourage increased involvement [10, 11, 12]. Despite more widespread funding and collaboration efforts, the vaccine ecosystem remains deeply unequal. Focusing on the period running between 2007 and 2014, a time marked by strong resource infusion from major public funders, these analyses provide new insights into how the resource landscape has shifted, where funding is highly concentrated, and how different donors and funders are connected. The results provide a foundation for global health researchers, policymakers, and practitioners to better understand prevailing dynamics as a means of informing collective efforts to respond to emergent health needs. With the beginning of the COVID-19 pandemic, there was a massive surge of public and private funding to support vaccine development activities. It is hypothesized that to respond to the health needs of the world's poorest populations, public and non-market mechanisms are unlikely to be sufficient. The WTO Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) is a barrier to the "sharing" of knowledge on how to produce these vaccines. Gavi, the Vaccine Alliance, was not designed to coordinate the procurement and allocation of doses on a global scale for outbreaks [13, 10, 14].

Challenges in Vaccine Distribution

As COVID-19 vaccination campaigns gain momentum worldwide, significant challenges remain. While vaccination campaigns are well underway in many high-income countries, lower- and middle-income nations struggle to access vaccines. These challenges highlight global health inequities related to the development and distribution of vaccines [15, 16, 17].

International Partnerships and Collaborations

In response to the COVID-19 pandemic, an unprecedented number of international partnerships and collaborations have been established, including collaborative research and development, knowledge

sharing, technology transfer, capacity building, and distribution agreements. G7 leaders committed to "ensure equitable access to vaccines, tests and treatments around the world" and emphasized their support for the Access to COVID-19 Tools (ACT) Accelerator and its COVAX facility. The 74th World Health Assembly passed resolutions on "COVID-19 response" and "Global strategy and plan of action on public health, innovation and intellectual property", calling for voluntary pooling and licensing of patents and the sharing of knowledge, data and intellectual properties. Public and private entities, including countries, vaccine suppliers, civil society organizations, manufacturers associations, research institutes, and multilateral agencies, declared their commitment to open sharing of data, knowledge, technology, and intellectual protections to boost vaccine production and supply, particularly in low- and middle-income countries [18, 19, 20]. Global collaborations in vaccine development and distribution have always been an important health policy issue, both from a global public health situation, as well as from the consequential socioeconomic consequences of a novel infectious disease outbreak. The COVID-19 pandemic has highlighted the critical need for a rapid and global approach to disease control and prevention. Since the beginning of the crisis, the dialogue, resource sharing, and cooperation between countries and global organizations have been established on an unprecedented level. These include the pooled procurement of essential supplies and vaccines through negotiated agreements, the imposition of export restrictions, and the discussions of resolving intellectual property rights barriers. These measures build a global perspective on the prevalence and control of the disease [21, 22, 23].

Technological Innovations in Vaccine Development and Distribution

The ongoing COVID-19 pandemic has underscored the necessity for global collaborations to develop and distribute vaccines against infectious diseases. In the present article, the topic is highlighted by examining technological innovations that have paved the way for recent breakthroughs in these areas. In particular, it discusses: (i) recent developments in vaccine technologies that have made it possible for multiple vaccines against COVID-19 to be rapidly developed and deployed; (ii) the role of digital health, data analytics, and artificial intelligence in optimizing vaccine deployment, particularly in the context of the challenges brought about by rapid adoption. The potential benefits of the technologies and advanced data analytics are estimated for COVID-19 response in terms of minimizing the number of infections and health sector deaths. However, due to the rapid development and deployment of tools, emphasis is also placed on the challenges associated with the implementation of innovative technologies in real-world settings, particularly the integration of new tools and data-driven decision-making into the complex and varying landscape of existing healthcare systems. Technological advances are deemed crucial advancements in vaccine development and distribution, essential to enhance the safety and efficacy of vaccines and ensure global health security. Further, these recent technological advancements offer an unprecedented opportunity to immunize populations around the world against a quickly evolving and long-term epidemiological threat. As such, investments and ongoing research are necessary to realize these goals, highlighting the importance of mitigation of vaccine hesitancy and the fostering of global collaboration. With further research and investment, these innovations have the potential to revolutionize the response to emerging infectious diseases. A few months into the COVID-19 pandemic, governments around the world announced nationwide lockdowns affecting billions of lives. While the pandemic itself was unexpected, the urgent need for a vaccine to mitigate its spread was not [24, 25, 26].

CONCLUSION

Global collaborations in vaccine development and distribution have become more critical than ever in the wake of the COVID-19 pandemic. While the rapid production and deployment of vaccines showcased unprecedented scientific and logistical achievements, it also exposed deep inequalities in access. Effective vaccine distribution requires coordinated efforts among governments, pharmaceutical companies, NGOs, and international organizations. Technological advancements, including AI, digital health solutions, and novel vaccine platforms, have played a pivotal role in optimizing vaccine development and delivery. However, challenges such as intellectual property restrictions, funding disparities, and vaccine hesitancy must be addressed. Moving forward, strengthening global health governance, enhancing transparency in vaccine allocation, and fostering innovation will be key to ensuring equitable immunization strategies. By learning from the current pandemic, the global community can establish a more robust framework for future infectious disease outbreaks, ultimately safeguarding global health security.

REFERENCES

1. Privor-Dumm L, Excler JL, Gilbert S, Karim SS, Hotez PJ, Thompson D, Kim JH. Vaccine access, equity and justice: COVID-19 vaccines and vaccination. BMJ global health. 2023 Jun 1;8(6):e011881. bmj.com
2. Bolcato M, Rodriguez D, Feola A, Di Mizio G, Bonsignore A, Ciliberti R, Tettamanti C, Trabucco Aurilio M, Aprile A. COVID-19 pandemic and equal access to vaccines. Vaccines. 2021 May 21;9(6):538. mdpi.com
3. Webb Hooper M, Nápoles AM, Pérez-Stable EJ. No populations left behind: vaccine hesitancy and equitable diffusion of effective COVID-19 vaccines. Journal of General Internal Medicine. 2021 Jul;36(7):2130-3. springer.com
4. Li X, Mukandavire C, Cucunubá ZM, Londono SE, Abbas K, Clapham HE, Jit M, Johnson HL, Papadopoulos T, Vynnycky E, Brisson M. Estimating the health impact of vaccination against ten pathogens in 98 low-income and middle-income countries from 2000 to 2030: a modelling study. The Lancet. 2021 Jan 30;397(10272):398-408. thelancet.com
5. Shattock AJ, Johnson HC, Sim SY, Carter A, Lambach P, Hutubessy RC, Thompson KM, Badizadegan K, Lambert B, Ferrari MJ, Jit M. Contribution of vaccination to improved survival and health: modelling 50 years of the Expanded Programme on Immunization. The Lancet. 2024 May 25;403(10441):2307-16. thelancet.com
6. Ryan J, Malinga T. Interventions for vaccine hesitancy. Current Opinion in Immunology. 2021 Aug 1;71:89-91.
7. Montero DA, Vidal RM, Velasco J, Carreño LJ, Torres JP, Benachi O MA, Tovar-Rosero YY, Oñate AA, O'Ryan M. Two centuries of vaccination: historical and conceptual approach and future perspectives. Frontiers in public health. 2024 Jan 9;11:1326154. frontiersin.org
8. Nieto-Sánchez C, Ochoa TJ, Onwuchekwa C, Ravinetto R, Verdonck K. Will a new pentavalent meningococcal ABCWY vaccine mark a milestone in protecting all those at risk from invasive meningococcal disease?. The Lancet Infectious Diseases. 2024 Dec 5.
9. O'Brien KL, Lemango E, Nandy R, Lindstrand A. The immunization Agenda 2030: A vision of global impact, reaching all, grounded in the realities of a changing world. Vaccine. 2024 Apr 8;42:S1-4.
10. Farlow A, Torreele E, Gray G, Ruxrungtham K, Rees H, Prasad S, Gomez C, Sall A, Magalhães J, Olliaro P, Terblanche P. The future of epidemic and pandemic vaccines to serve global public health needs. Vaccines. 2023 Mar 17;11(3):690. mdpi.com
11. Rojas-Botero ML, Fernández-Niño JA, Arregocés-Castillo L, Ruiz-Gómez F. Estimated number of deaths directly avoided because of COVID-19 vaccination among older adults in Colombia in 2021: an ecological, longitudinal observational study. F1000Research. 2022 Jul 7;11:198. nih.gov
12. Qaiser Gillani D, Gillani SA, Naeem MZ, Spulbar C, Coker-Farrell E, Ejaz A, Birau R. The nexus between sustainable economic development and government health expenditure in Asian countries based on ecological footprint consumption. Sustainability. 2021 Jun 16;13(12):6824. mdpi.com
13. Hotez PJ, Gilbert S, Saville M, Privor-Dumm L, Abdool-Karim S, Thompson D, Excler JL, Kim JH. COVID-19 vaccines and the pandemic: lessons learnt for other neglected diseases and future threats. BMJ Global Health. 2023 Jun 1;8(6):e011883. bmj.com
14. Asaduzzaman M, Khai TS, de Claro V, Zaman F. Global Disparities in COVID-19 Vaccine Distribution: A Call for More Integrated Approaches to Address Inequities in Emerging Health Challenges. Challenges. 2023 Oct 31;14(4):45.
15. Belshe WB, Alswang JM, Uplift-Brown AM, Chilenga L, Chipolombwe J, Seaman VY. Lessons learned from the Global Polio Eradication Initiative: A roadmap for the international COVID-19 vaccination campaign. Malawi Medical Journal. 2022 Dec 16;34(4):294-8.
16. Themelis S. Education and equalityde: bunking the myth of meritocracy. Educ. Form.. 2017 Jan 2;2(4):03-17.
17. Pedroso MN. A pobreza ea desigualdade: uma realidade brasileira no século XXI. Leituras de economia política. 2020(31):31-54.
18. Nguyen MH, Vuong QH. Evaluation of the Aichi Biodiversity Targets: The international collaboration trilemma in interdisciplinary research. Pacific Conservation Biology. 2021 Dec 14;28(6):517-31.

19. Druedahl LC, Minssen T, Price WN. Collaboration in times of crisis: A study on COVID-19 vaccine R&D partnerships. Vaccine. 2021 Oct 8;39(42):6291-5.
20. Mncube V, Mutongoza BH, Olawale E. Managing higher education institutions in the context of COVID-19 stringency: Experiences of stakeholders at a rural South African university. Perspectives in Education. 2021 Mar 12;39(1):390-409.
21. Eccleston-Turner M, Upton H. International collaboration to ensure equitable access to vaccines for COVID-19: the ACT-Accelerator and the COVAX facility. The Milbank Quarterly. 2021 Jun;99(2):426-49.
22. Excler JL, Privor-Dumm L, Kim JH. Supply and delivery of vaccines for global health. Current opinion in immunology. 2021 Apr 10;71:13. nih.gov
23. Pilkington V, Keestra SM, Hill A. Global COVID-19 vaccine inequity: failures in the first year of distribution and potential solutions for the future. Frontiers in Public Health. 2022 Mar 7;10:821117.
24. Spadaro B. COVID-19 vaccines: challenges and promises of trials, manufacturing and allocation of doses. Future Drug Discovery. 2021 Mar 1;3(1):FDD57.
25. Sharma DK, Makhija TK. Unprecedented Dimensions in Global Economy: Bound to Happen. Available at SSRN 4936171. 2024 Aug 7.
26. Cameron A, Esiovwa R, Connolly J, Hursthouse A, Henriquez F. Antimicrobial Resistance as a Global Health Threat: The Need to Learn Lessons from the COVID-19 Pandemic. Global Policy. 2022 May;13(2):179-92. wiley.com

CITE AS: Asiimawe Masika Agnovia (2025). Global Collaborations in Vaccine Development and Distribution. RESEARCH INVENTION JOURNAL OF PUBLIC HEALTH AND PHARMACY 4(1): 12-16. https://doi.org/10.59298/RIJPP/2025/411216